There is expected to be activity at the European Medicines Agency this week regarding the re-evaluation of PharmaMar’s EU marketing application for Aplidin (plitidepsin), which was rejected in 2018 in a decision that was later ruled to be unfair due to conflicts of interest issues at the agency.
PharmaMar’s Aplidin Back On EMA’s Agenda After Conflict Of Interest Controversy
The European Medicines Agency is re-evaluating the marketing application for Aplidin. The initial application was rejected in 2018, but that rejection was revoked last year following a court case for another company’s drug that clarified impartiality requirements for experts consulted by the EMA.
